Literature DB >> 15787956

Drug insurance utilization management policies and "reference pricing": an illustrated commentary on the article by Vittorio Maio and colleagues.

Malcolm Maclure1.   

Abstract

Mesh：

Year:  2005        PMID： 15787956      PMCID： PMC2690388          DOI： 10.1111/j.0887-378X.2005.00338.x

Source DB:  PubMed          Journal:  Milbank Q        ISSN： 0887-378X            Impact factor:   4.911


× No keyword cloud information.
  11 in total

1.  Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly.

Authors:  Thomas K Hazlet; David K Blough
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.

Authors:  John K Marshall; Paul V Grootendorst; Bernie J O'Brien; Lisa R Dolovich; Anne M Holbrook; Adrian R Levy
Journal:  CMAJ       Date:  2002-06-25       Impact factor: 8.262

3.  Health care at a premium.

Authors:  Jeremiah Hurley
Journal:  CMAJ       Date:  2004-06-22       Impact factor: 8.262

4.  National pharmacare: a dog's tale.

Authors:  Aslam H Anis
Journal:  CMAJ       Date:  2004-09-14       Impact factor: 8.262

Review 5.  Pharmacy utilization and the Medicare Modernization Act.

Authors:  Vittorio Maio; Laura Pizzi; Adam R Roumm; Janice Clarke; Neil I Goldfarb; David B Nash; David Chess
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

6.  Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.

Authors:  P V Grootendorst; L R Dolovich; B J O'Brien; A M Holbrook; A R Levy
Journal:  CMAJ       Date:  2001-10-16       Impact factor: 8.262

7.  Prescription duration after drug copay changes in older people: methodological aspects.

Authors:  Sebastian Schneeweiss; Malcolm Maclure; Stephen B Soumerai
Journal:  J Am Geriatr Soc       Date:  2002-03       Impact factor: 5.562

8.  Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Authors:  Sebastian Schneeweiss; Stephen B Soumerai; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Alexander M Walker
Journal:  CMAJ       Date:  2002-03-19       Impact factor: 8.262

9.  Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

Authors:  Sebastian Schneeweiss; Stephen B Soumerai; Malcolm Maclure; Colin Dormuth; Alexander M Walker; Robert J Glynn
Journal:  Clin Pharmacol Ther       Date:  2003-10       Impact factor: 6.875

10.  Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.

Authors:  Sebastian Schneeweiss; Colin Dormuth; Paul Grootendorst; Stephen B Soumerai; Malcolm Maclure
Journal:  Med Care       Date:  2004-07       Impact factor: 2.983
View more
  4 in total

1.  Reference drug programs: effectiveness and policy implications.

Authors:  Sebastian Schneeweiss
Journal:  Health Policy       Date:  2006-06-13       Impact factor: 2.980

2.  Time series evaluation of an intervention to increase statin tablet splitting by general practitioners.

Authors:  Jennifer M Polinski; Sebastian Schneeweiss; Malcolm Maclure; Blair Marshall; Samuel Ramsden; Colin Dormuth
Journal:  Clin Ther       Date:  2011-02       Impact factor: 3.393

3.  Reference pricing system and competition: case study from Portugal.

Authors:  Conceiçăo Portela
Journal:  Croat Med J       Date:  2009-10       Impact factor: 1.351

4.  Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications.

Authors:  Colin R Dormuth; Malcolm Maclure; Robert J Glynn; Peter Neumann; Alan M Brookhart; Sebastian Schneeweiss
Journal:  Clin Ther       Date:  2008       Impact factor: 3.393
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.